Solution offers researchers the power to perform glycan screening of large sample cohorts enabling better decisions in clone selection and cell culture optimization January 30, 2018 Framingham, MA — SCIEX, a global leader in life science analytical technologies, today announced the launch of the new C100HT for qualitative glycan screening in biopharma. Combined with SCIEX’s award-winning... Read more
Shimadzu Corporation has released the Nexera Mikros, a micro flowrate-compatible liquid chromatograph mass spectrometer. The Nexera Mikros maintains the durability and operability of liquid chromatography mass spectrometry (LC-MS) systems while providing at least ten times the sensitivity. In recent years, in the field of pharmaceutical development, analysis has occasionally been performed on trace amounts of... Read more
Germantown, Maryland, and Hilden, Germany, January 18, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA supplement extending the indications for use of QIAGEN’s therascreen® EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer Ingelheim’s... Read more
Chalfont St Giles, UK and Changxing, Zhejiang, China – 23 January 2018 — Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, has chosen GE Healthcare’s FlexFactory, a biomanufacturing platform based on single-use technologies, for its new facility located in Changxing, Zhejiang in China. The new facility will mainly be used... Read more
The new facility will support a robust pipeline of biopharmaceuticals, including a biosimilar to Enbrel® for the treatment of rheumatoid arthritisChalfont St Giles, UK and Changxing, Zhejiang, China – 23 January 2018 – Clover Biopharmaceuticals, a biotechnology company focused on developing novel https://www.genewsroom.com/press-releases/clover-biopharmaceuticals-selects-ges-flexfactory-biomanufacturing-platform-its-new Read more
2018 2018/01/19 First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR gene therapy against synovial sarcoma in Japan Kusatsu/Shiga, Japan — January 17, 2018 — Takara Bio Inc. (Takara Bio), today announced that the first patient with synovial sarcoma has been enrolled into NY-ESO-1・siTCR gene therapy (TBI-1301) phase I/II clinical trial in Japan on January... Read more
January 8, 2018 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, amped up the protein quant range on Lunatic today, making measurements of up to 250 mg/mL IgG a cinch for biologics researchers. High-concentration biologics don’t have to be administered as often, plus patients... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS) today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina’s next-generation sequencing (NGS) technology. The collaboration is a significant step toward China Food and Drug Administration (CFDA) review and approval, and serves as a starting point to deliver... Read more
Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia This chemotherapy-free combination showed improvements across multiple efficacy measures compared to bendamustine plus MabThera/Rituxan in the pivotal MURANO trial... Read more
Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia This chemotherapy-free combination showed improvements across multiple efficacy measures compared to bendamustine plus MabThera/Rituxan in the pivotal MURANO trial... Read more